Corcept attributes its revenue boost to better recognition of Cushing’s
Corcept Therapeutics is expecting to earn nearly $500 million in revenue this year, which is due in large part to the increased recognition of Cushing’s syndrome, the company noted in a recent corporate update. Corcept, which markets Korlym (mifepristone) — a therapy approved to control high blood sugar in…